Search clinical trials for: Anti-IL17A/F Nanobody

Total 17 results

Merck KGaA, Darmstadt, Germany

Completed

Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

Psoriasis

Germany
MoonLake Immunotherapeutics AG

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
MoonLake Immunotherapeutics AG

Recruiting

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors

Solid Tumor

China
Peking University Cancer Hospital & Institute

Recruiting

PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

Colorectal Cancer | Lung Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Solid Tumor

China
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

Melanoma | Lung Cancer | PD-L1 | PET/CT

China
MoonLake Immunotherapeutics AG

Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Germany, United States, Bulgaria, Canada, Ireland, Netherlands, Poland
Ablynx, a Sanofi company

Completed

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (TITAN)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
Wuhan Union Hospital, China
Shanghai Cell Therapy Group Co.,Ltd

Unknown

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Non-small-cell Lung Cancer | Mesothelioma

China
Merck KGaA, Darmstadt, Germany

Completed

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

Osteoarthritis, Knee

Denmark
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers

Healthy

Denmark
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
Ablynx

Completed

Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Poland, Hungary, Czechia
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Myeloma

China
Boehringer Ingelheim

Completed

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Healthy
Ablynx

Terminated

First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4

Healthy Volunteers

Netherlands

3

Subscribe